Abstract
Trospium chloride and oxybutynin are two antimuscarinergic agents used in the treatment of unstable bladder, urge incontinence, combined stress urge incontinence and detrusor hyperreflexia. The possibility that these two drugs produce changes in central nervous electrical activity was examined in an open, prospective, phase I study involving 12 volunteers.
Quantitative evaluation of the multichannel electroencephalogram obtained from young healthy volunteers showed statistically significant decreases in alpha and beta1 activity after oxybutynin, but not after intravenous or oral administration of trospium chloride. The biological activity of both drugs was ascertained by continuous simultaneous recording of the heart rate. A decrease in heart rate was detected after oral administration of oxybutynin, and an increase was seen after i.v. administration of trospium chloride.
The results suggest that trospium chloride is less likely to produce central nervous adverse effects than to oxybutynin.
Similar content being viewed by others
References
Andersson K-E (1988) Current concepts in the treatment of disorders of micturition. Drugs 35: 477–494
Brown JH (1989) Atropine, scopolamine, and related antimuscarinergic drugs. In: Gilman AG et al (eds) Goodman and Gilman's The pharmacological basis of therapeutics. Pergamon, New York, pp 150–165
Dimpfel W, Schober F, Spüler M (1993) The influence of caffeine on human EEG under resting conditions and mental loads. Clin Investig 71: 197–207
Dimpfel W (1993) The new route to brain mapping. Med Technol Int, pp 24–25
Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchulez A (1988) The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 35: 515–520
Downie JW (1993) Pharmacological treatment of incontinence and voiding disorders. Curr Opin Urol 3: 280–283
Hughes KM, Lang JCT, Lazare R, Gordon D, Staunton SL, Malone-Lee J, Geraint M (1992) Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 22: 859–869
Langguth P, Mutschler E (1987) Lipophilisation of hydrophilic compounds. Arzneimittelforschung Drug Res 37: 1362–1366
Mitchelson F (1988) Muscarinic receptor differentiation. Pharmacol Ther 37: 357–423
Ouslander JG, Blausten J, Connor A, Orzeck S, Yong C-L (1988) Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 140: 47–50
Pitschner HF, Schlepper M, Schulte B, Volz C, Palm D, Wellenstein A (1989) Selective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol Sci 10 [Suppl]: 92–96
Pfeiffer A, Schmidt T, Höller T, Herrmann H, Pehl C, Wendl B, Kaess H (1993) Effect of trospium chloride on gastrointestinal motility in humans. Eur J Clin Pharmacol 44: 219–223
Pfeiffer A, Schmidt T, Höller T, Herrmann H, Pehl C, Wendl B, Kaess A (1990) Die Wirkung des Spasmolytikums Trospiumchlorid auf die Gallenblasenkontraktion, die Magenentleerung, die orocoecale Transitzeit und den gastroösophagealen Reflux. Klin Wochenschr 68 [Suppl XIX]: 46
Sachs L (1992) Angewandte Statistik, 7th edn. Springer, Berlin Heidelberg New York, pp 414–418
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pietzko, A., Dimpfel, W., Schwantes, U. et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 47, 337–343 (1994). https://doi.org/10.1007/BF00191165
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00191165